1 Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol 2011; 48: 1-9.
2 Ruan W, Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 2010; 47: 5-14.
3 Spiliotaki M, Markomanolaki H, Mela M, et al. Targetingthe insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer 2011;73: 158-65.
4 Heidegger I, Pircher A, Klocker H,et al. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 2011; 11: 701-7.
5 Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 154-60.
6 Galea CA, Mobli M, McNeil KA, et al. Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie 2012; 94: 608-16.
7 Duan C, Ren H, Gao S. Insulin-like growth factors(IGFs), IGF receptors and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 2010; 167: 344-51.
8 Wolf E, Lahm H, Wu M, et al. Effects of IGFBP-2 overexpression in vitro and in vivo. Pediatr Nephrol 2000; 14: 572-8.
9 Reeve JG, Schwander J, Bleehen NM. IGFBP-2: an important regulator of insulin-like growth factor action in human lung tumours? Growth Regul 1993; 3: 82-4.
10 Galea CA, Mobli M, McNeil KA, et al. Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie 2012; 94: 608-16.
11 Migita T, Narita T, Asaka R, et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGFindependent antiapoptotic effect via caspase-3. Am J Pathol 2010; 176: 1756-66.
12 Planque C, Kulasingam V, Smith CR, et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009; 8: 2746-58.
13 Kim JS, Kim ES, Liu D, et al. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 2012; 118: 2454-65.
14 Yazawa T, Sato H, Shimoyamada H, et al. Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009; 175: 976-87.
15 Yu CJ, Wang CL, Wang CI, et al. Comprehensive Proteome Analysis of Malignant Pleural Effusion for Lung Cancer Biomarker Discovery by Using Multidimensional Protein Identification Technology. J Proteome Res 2011; 10: 4671-82.
16 Olchovsky D, Shimon I, Goldberg I, et al. Elevated insulinlike growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion. Acta Oncol 2002; 41: 182-7.
17 Matuschek C, Rudoy M, Peiper M, et al. Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res 2011; 16: 451-6.
18 Grimberg A, Coleman CM, Shi Z, et al. Insulin-Like Growth Factor Factor Binding Protein-2 is a Novel Mediator of p53 Inhibition of Insulin-Like Growth Factor Signaling. Cancer Biol Ther 2006; 5: 1408-14.
19 Sato H, Yazawa T, Suzuki T, et al. Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006; 169: 1550-66.
20 Ambrosini-Spaltro A, Farnedi A, Montironi R, et al. IGFBP-2 as an immunohistochemical marker for prostatic adenocarcinoma. Appl Immunohistochem Mol Morphol 2011; 19: 318-28.
21 Uzoh CC, Holly JM, Biernacka KM, et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 2011; 104: 1587-93.
22 Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007; 104: 5563-8.
23 Degraff DJ, Aguiar AA, Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009; 1: 115-30.
24 Degraff DJ, Malik M, Chen Q, et al. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 2007; 213: 261-8.
25 Probst-Hensch NM, Steiner JH, Schraml P, et al. IGFBP-2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 2010; 16: 1025-32.
26 So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944-54.
27 Park KH, Gad E, Goodell V, et al. Insulin-like growth factorbinding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008; 68: 8400-9.